Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Intravenous (IV) Palifosfamide-tris Administered in Combination With IV Etoposide and IV Carboplatin in Patients With Malignancies for Which Etoposide and Carboplatin Are an Appropriate Choice

NCT01242072 is registered in ClinicalTrials.gov with Alaunos Therapeutics as lead sponsor.

NCT NCT01242072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01242072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Intravenous (IV) Palifosfamide-tris Administered in Combination With IV Etoposide and IV Carboplatin in Patients With Malignancies for Which Etoposide and Carboplatin Are an Appropriate Choice
Lead sponsor
Alaunos Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2010
Completion date
July 16, 2012
Enrollment
22 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, malignancy, non small cell lung cancer, osteosarcoma, ovarian cancer, small cell lung cancer, testicular cancer, thymoma